

ANTIBIOTIC SENSITIVITY CHART

Created by James McCormack, BSc(Pharm), PharmD and Franklin Lai, BSc(Pharm), PharmD,
with assistance from Drs. Tim Lau, Cecilia Ngai, and Marion Chow
Faculty of Pharmaceutical Sciences, University of British Columbia, and Vancouver Hospital, Vancouver, BC

| Bacteria | Gram Positive Coccii | | | | Gram Negative Bacilli | | | | | | Gram Negative Cocacobacilli | | Anaerobes | | Atypicals | | |
|-------------------|---|------------------------------|--------------------------------------|---|---|-------------------------------|------------------------|------------------------|--|--|-----------------------------|---------------------------------|---------------------------|--|---------------------------|--------------------------|---------------------------------|
| | Streptococci | | Staphylococci | | Gram Negative Bacilli | | | | | | Gram Negative Cocacobacilli | | Anaerobes | | Atypicals | | |
| Site of infection | CNS, oral, respiratory tract, heart, skin | intrabdominal, urinary tract | Skin, prosthetics | Oral, respiratory tract, heart, skin, bones/joint | Respiratory, intrabdominal, urinary tract, and others | | | | | | Central nervous system | Pelvic inflammatory disease/STI | Oral, respiratory tract | Intrabdominal, pelvic inflammatory disease | Intrabdominal | Respiratory tract | Pelvic inflammatory disease/STI |
| Penicillins | Penicillin V/G | | | | | | | | | | Penicillin G-IV | | Penicillin V/G | | | | |
| | Amoxicillin/Ampicillin | | | | Amoxicillin | | | | | | Ampicillin IV | | Amoxicillin/Ampicillin | | | | |
| | Amoxicillin-clavulanate | | Amoxicillin-clavulanate | | Amoxicillin-clavulanate | Avoid in serious infections | | | | | | | Amoxicillin-clavulanate | | | | |
| | Piperacillin-tazobactam | | Piperacillin-tazobactam | | Piperacillin-tazobactam | Avoid in serious infections | | | | Piperacillin-tazobactam | | | Piperacillin-tazobactam | | | | |
| Cephalosporines | Cefazolin/Cephalexin | | Cefazolin/Cephalexin | | Cefazolin/Cephalexin | | | | | | | | Cefazolin/Cephalexin | | | | |
| | Cefuroxime | | Cefuroxime | | Cefuroxime | | | | | | | | Cefuroxime | | | | |
| | Cefotaxim | | Cefotaxim | | Cefotaxim | | | | | | | | Cefotaxim | | | | |
| | Ceftriaxone/Cefotaxime | | Ceftriaxone/Cefotaxime | | Ceftriaxone/Cefotaxime | | | | | | | | Ceftriaxone/Cefotaxime | | | | |
| | Cefixime | | Cefixime | | Cefixime | | | | | | | | Cefixime | | | | |
| | Cefipime | | Cefipime | | Cefipime | Unpredictable activity | | | | Cefipime | | | Cefipime | | | | |
| | | | | | Cefiderocol (SAP) | | | | | | | | Cefiderocol (SAP) | | | | |
| | | | | | Ceftriaxane-tazobactam | | | | | Ceftriaxane-tazobactam | | | Ceftriaxane-tazobactam | | | | |
| | | | | | Ceftazidime-avibactam (SAP) | | | | | Ceftazidime | | | | | | | |
| | Ceftazoline (SAP) | | Ceftazoline (SAP) | | | | | | | | | | Ceftazoline (SAP) | | | | |
| Monobactams | Ceftobiprole | | Ceftobiprole | | | | | | | | | | Ceftobiprole | | | | |
| | | | | | Aztreonam (SAP) | | | | | Only in Combination with CFZ-AVI (SAP) | | Attreonam (SAP) | | | | | |
| Carbapenems | Meropenem/Imipenem | | Meropenem/Imipenem | | | Meropenem/Imipenem | | | | Meropenem/Imipenem | | | Meropenem/Imipenem | | | | |
| | Ertapenem | | Ertapenem | | | Ertapenem | | | | | | | Ertapenem | | | | |
| | Imipenem-relebactam (SAP) | | Imipenem-relebactam (SAP) | | | Imipenem-relebactam (SAP) | | | | | | | Imipenem-relebactam (SAP) | | | | |
| Macrolides | Erythromycin | | Erythromycin | | | | | | | | | | | Erythromycin | | | |
| | Clarithromycin/Azithromycin | | Clarithromycin/Azithromycin | | | | | | | | | | | Clarithromycin/Azithromycin | | | |
| Tetracyclines | Tetracycline/Doxycycline/Minocycline | | Tetracycline/Doxycycline/Minocycline | | | | | | | | | | | Tetracycline/Doxycycline/Minocycline | | Tetracycline/Doxycycline | |
| | Tigecycline | | Tigecycline | | | | | | | | | | | Tigecycline | | Tigecycline | |
| Fluoroquinolones | | | | | Ciprofloxacin/Norfloxacin (Only bladder infections for Norfloxacin) | | | | | | | | | Ciprofloxacin | | | |
| | Levofloxacin/Moxifloxacin | | | | Levofloxacin/Moxifloxacin | | | | | | | | Levofloxacin/Moxifloxacin | Moxifloxacin | Levofloxacin/Moxifloxacin | | |
| Aminoglycosides | | | | | Gentamicin/Tobramycin/Amikacin | | | | | Amikacin | | | | | | | |
| | | | | | Colistin/Polymyxin B | | | | | | | | Colistin | Polymyxin B | | | |
| Polymyxin | Clindamycin | | Clindamycin | | | | | | | | | | | Clindamycin | | Clindamycin only | |
| | Vancomycin/Daptomycin/Dalbavancin | | | | | | | | | | | | | Vancomycin/Daptomycin/Dalbavancin | | Vancomycin (PO) | |
| Lincosamides | | | | | | | | | | | | | | | | | |
| | Lipopeptides/Lipoglycopeptides | | | | | | | | | | | | | | | | |
| Oxazolidinones | | | | | Linezolid | | | | | | | | | Linezolid | | | |
| | Trimethoprim-Sulfamethoxazole | | Trimethoprim-sulfamethoxazole | | | Trimethoprim-sulfamethoxazole | | | | | | | | | | | |
| Chloramphenicol | Chloramphenicol | | | | | Chloramphenicol | | | | | | | | Chloramphenicol | | | |
| | | | | | | | | | | | | | | | Metronidazole | | |
| Metronidazole | | | | | | | | | | | | | | | | | |
| | Nitrofurantoin/Fosfomycin | | Nitrofurantoin/Fosfomycin | | | Nitrofurantoin/Fosfomycin | Unpredictable activity | Unpredictable activity | | | | | | Rifampin | | | |
| Rifamycin | | | | | Rifampin | | | | | | | | | | | | |
| | Fidaxomicin | | | | | | | | | | | | | | Fidaxomicin | | |

Rifampin should not be used alone for Staphylococcal infections.

Clarithromycin, Azithromycin, Erythromycin, and Telithromycin: the antibiotics listed are active against *E. faecalis*, but have limited activity for *E. faecium*.

Clarithromycin as well as beta-lactamase inhibitor combinations have in-vitro activity for *HfCK-Yes* organisms, but may induce production of beta-lactamases.

Tigecycline is active against *HfCK-Yes* organisms, but for *Proteus* spp. it depends on local susceptibility data.

SAP = Special Access Program (i.e., not marketed but available from Health Canada)